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Abstract γ-Secretase inhibitors (GSIs) are potential ther-
apeutic agents for Alzheimer’s disease (AD); however,
trials have proven disappointing. We addressed the possi-
bility that γ-secretase inhibition can provoke a rebound
effect, elevating the levels of the catalytic γ-secretase
subunit, presenilin-1 (PS1). Acute treatment of SH-
SY5Y cells with the GSI LY-374973 (N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl es-
ter, DAPT) augments PS1, in parallel with increases in
other γ-secretase subunits nicastrin, presenilin enhancer
2, and anterior pharynx-defective 1, yet with no increase
in messenger RNA expression. Over-expression of the C-
terminal fragment (CTF) of APP, C99, also triggered an
increase in PS1. Similar increases in PS1 were evident in
primary neurons treated repeatedly (4 days) with DAPT or
with the GSI BMS-708163 (avagacestat). Likewise, rats
examined after 21 days administered with avagacestat
(40 mg/kg/day) had more brain PS1. Sustained γ-
secretase inhibition did not exert a long-term effect on
PS1 activity, evident through the decrease in CTFs of
APP and ApoER2. Prolonged avagacestat treatment of
rats produced a subtle impairment in anxiety-like behav-
ior. The rebound increase in PS1 in response to GSIs must
be taken into consideration for future drug development.
Keywords Alzheimer’s disease . Presenilin-1 . γ-Secretase
inhibitor . Therapy
Introduction
Alzheimer’s disease (AD) is the most common dementia
in the elderly, and it is characterized by extracellular de-
posits of aggregated β-amyloid (Aβ) peptides and accu-
mulation of intracellular tangles of the abnormally
hyperphosphorylated microtubule-associated protein tau
(P-tau) [1]. According to the amyloid cascade hypothesis,
which is the most prevalent view on AD pathogenesis, the
disease pathophysiology is triggered by an excess of neu-
rotoxic Aβ peptides, potentially in combination with oth-
er genetics and risk factors [2]. Drug candidates targeting
Aβ have dominated AD drug development programs for
the past three decades [3], and accordingly, targets for
each individual step in this cascade have been developed,
with β/γ-secretase inhibitors representing one particular
opportunity for front-line therapy.
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The Aβ peptide is generated by successive proteolytic pro-
cessing of the amyloid precursor protein (APP) by secretases.
APP is a type I transmembrane spanning glycoprotein that is
first processed by either α- or β-secretase, followed by γ-
secretase cleavage. β- and γ-secretase cleavage generate Aβ
peptides of variable amino acid length, being the most abun-
dant the Aβ40 peptide [4] while Aβ42 appears to be the most
amyloidogenic [5]. The major neuronal β-secretase is the
beta-site APP-cleaving enzyme 1 (BACE1) [6], while the γ-
secretase enzyme complex contains four essential subunits:
presenilin-1 (or presenilin-2), nicastrin, anterior pharynx-
defective 1 (APH1), and presenilin enhancer 2 (PEN2) [7].
γ-Secretase acts an aspartyl protease, which catalytic core is
presenilin-1 (PS1), being its dysfunction associated with the
pathological development of AD [8]. Thus, compounds that
inhibit γ-secretase, targeting PS1, are potential therapeutic
agents for AD.
Preclinical studies clearly established that γ-secretase
inhibitors (GSIs) reduce brain Aβ in rodent models and
also reverse Aβ-induced cognitive deficits in the AD
Tg2576 mice [9]. However, the therapeutic effect of such
drugs in humans has fallen below expectation, with no
demonstrated efficacy in clinical trials and even impaired
cognitive function in long-term treated subjects [10].
Problems of tolerability and dose-limiting effects during
clinical trials with GSIs may have compromised target
engagement for arriving to the minimum extent of Aβ
lowering for significant cognitive benefit in AD patients
(discussed in Toyn and Ahlijanian [11]). On the other
hand, a paradoxical increase of plasma Aβ levels has
been observed upon chronic treatment with a classical
GSI in transgenic animal [12]. Treatment of transgenic
mice and humans with other GSIs, including compounds
involved in clinical trials, may cause late rebound effects
on plasma Aβ levels [13–15]. These changes may be il-
lustrative of a rebound effect in reaction to inhibition by a
GSI-based therapy. To decipher why current GSIs fail to
improve the disease state may help to optimize future
drug development.
Upregulation of enzyme isoforms [16, 17], and also of
the specific enzyme targeted by the drug [18–20], is not
an uncommon phenomenon in reaction to inhibition, al-
though to our knowledge, this possible effect remains un-
explored in terms of GSI treatment. Interestingly, we re-
cently reported that an increase in acetylcholinesterase
could block γ-secretase activity and that this inhibition
initiates a feedback process that leads to a rebound effect,
elevating PS1 levels [21]. Here, we tested how GSIs af-
fect PS1 levels in cellular and animal models. As such, we
provide evidence that γ-secretase inhibition could pro-
voke a rebound increase in PS1, which may be of partic-
ular importance for the design of specific AD therapies
based on GSIs and related drugs.
Materials and Methods
Cell Cultures and Pharmacological Treatment with GSIs
SH-SY5Y cells (700,000 cells/well) were grown in six-well
plates for 24 h in Dulbecco’s modified Eagle’s medium
(DMEM) + GlutaMAX™ (Gibco® Life Technologies,
Paisley, UK) supplemented with 10% fetal bovine serum
(FBS; Gibco) and 100 μg/mL penicillin/streptomycin
(Gibco). The cells were treated with 5 μM of γ-secretase
inhibitor LY-374973: N-[N-(3,5-difluorophenacetyl)-L-ala-
nyl]-S-phenylglycine t-butyl ester (DAPT; Calbiochem®,
Merck KGaA) or the dimethyl sulfoxide (DMSO) vehicle
alone. Following an 18-h treatment, the cells were washed
twice with cold phosphate-buffered saline (PBS) and resus-
pended in 100 μL of ice-cold extraction buffer supplemented
with a cocktail of protease inhibitors: 50 mM Tris-HCl (pH
7.4), 150 mM NaCl, 5 mM EDTA, 1% (w/v) Nonidet P-40,
and 0.5% (w/v) Triton X-100. Cell lysates were sonicated and
centrifuged for 1 h at 70,000×g and 4 °C, and the extracts were
frozen at −80 °C for future analysis.
For some experiments, SH-SY5Y cells were transfected
with 4 μg of a construct that encodes the C-terminal 99 amino
acids of APP (amino acids 597–695), extending from the β-
secretase cleavage site to the C-terminus (a generous gift from
David H. Small). A pCI empty vector (Promega) served as the
negative control. These cells (7 × 105 cells/well) were then
seeded on 35-mm tissue culture dishes and transfected using
Lipofectamine® 2000 (Thermo Scientific™) according to the
manufacturer’s instructions. After 2 days in culture, the cells
and culture supernatants were harvested separately, and the
cell culture supernatants were cleared by centrifugation at
1000×g for 10 min at 4 °C. The cells were then washed with
PBS and solubilized as described above. C-terminal fragment
of APP (APP-CTF) levels were assayed in Western blots to
determine transfection efficiency.
To culture primary cortical neurons, cortical lobes from
E16.5 mice embryos were trypsinized and dissociated in
Hank’s balanced salt solution (Life Technologies). Neurons
were plated onto 35-mm dishes (1.3 × 106 cells/dish) and
maintained in Neurobasal medium (Invitrogen) containing
B27 supplement (Gibco BRL), 100 IU/mL penicillin,
100 μg/mL streptomycin, and 2 mM glutamine. After 7 days
in culture, the cortical neurons were treated with 2 μM of
DAPT or the GSI avagacestat (BMS-708163; from Bristol-
Myers Squibb) for four consecutive days and analyzed on
day 5, 18 h after the last dose. The cells were washed with
PBS and solubilized as described above.
Cell viability was measured using the tetrazolium assay
(MTS; CellTiter 96® AQueous Assay, Promega) according
to the manufacturer’s instructions. Cells were cultured in 96-
well plates and treated with GSIs as previously stated. MTS
was added after GSI treatment, cells were incubated for 4 h,
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and then viability was determined by measuring the absor-
bance at 490 nm in amicroplate reader (InfiniteM200, Tecan).
Animals and Tissue Preparation
All animal procedures were approved by the Animal Care and
Use Committees at the UniversidadMiguel Hernández and by
Centro Principe Felipe (2016A/SC/PEA/00127). Wistar male
rats that weighed 250–300 g at the beginning of GSI admin-
istration were used. The rats were orally administered the
avagacestat (40 mg/kg) or vehicle alone (polyethylene glycol)
using a single or once-a-day dose for 4 or 21 days (n = 10 for
each group), and they were sacrificed ~ 4 h after the final
administration of avagacestat. Cerebrospinal fluid (CSF) sam-
ples (50–60 μL) were collected by cisternal puncture with a
needle inserted in the suboccipital region through the atlanto-
occipital membrane, with a single incision into the subarach-
noid space [22]. CSF samples were centrifuged at 1000×g for
10 min at 4 °C, and the supernatants were stored at −80 °C. In
addition, the rat’s brain was removed and their cerebral corti-
ces were dissected out and stored at −80 °C. Hemi-cortices
were thawed slowly at 4 °C and homogenized (10% w/v) in
extraction buffer: 50 mM Tris-HCl (pH 7.4)/500 mM
NaCl/5 mM EDTA/1% (w/v) Nonidet P-40/0.5% (w/v)
Triton X-100, supplemented with a cocktail of protease inhib-
itors [23]. The homogenates were sonicated and centrifuged,
as indicated above, and the supernatants were collected and
frozen at −80 °C. Protein concentrations were determined
using the bicinchoninic acid method (Pierce, Rockford, IL,
USA). The other hemi-cortices were reserved for messenger
RNA (mRNA) analysis (see below).
Western Blotting
Cell (20 μg) and brain extracts (40 μg) and CSF samples
(30 μL) were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) under fully
reducing conditions. Samples were denatured at 50 °C for
15 min to analyze PS1 or, alternatively, at 98 °C for 5 min
for other proteins. The proteins separated were transferred to
nitrocellulose membranes (Schleicher and Schuell Bioscience
GmbH) and probed with a PS1 antibody raised against amino
acids 1–20 (antibody 98/1; see Evin et al. [24]). Protein ex-
tracts from cell cultures were also probed for other γ-secretase
subunits using the following antibodies: mouse anti-nicastrin
(Millipore), rabbit anti-PEN2 (Sigma), and rabbit anti-APH1
(which recognizes both the APH1A and APH1B homologs;
Sigma).
Brain extracts were also assayed for the CTF of APP or
ApoER2 using the monoclonal anti-APP C-terminal antibody
C1-6.1 (Covance) or a polyclonal antiserum against the C-
terminal of ApoER2 (Abcam). Alternatively, the anti-APP
monoclonal antibody 6E10 (Covance) was used. A rabbit
anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
antibody (Abcam) was used as a loading control. Western
blots for different antibodies were performed separately to
avoid re-probing the membranes. Antibody binding was de-
tected with the corresponding conjugated secondary antibody
(IRDye 680CW goat anti-mouse and IRDye 800RD goat anti-
rabbit; LI-COR Biosciences) and visualized on an Odyssey
CLx Infrared Imaging System (LI-COR Biosciences).
Densitometric quantification of the signal from immunoreac-
tive bands was obtained using LI-COR software (Image
Studio Lite).
RNA Isolation and the Analysis of γ-Secretase Subunit
Transcripts by qRT-PCR
The transcripts encoding PS1, nicastrin, PEN2, and two forms
of APH1 (APH1A and APH1B) were assayed. The total RNA
from rat brain hemi-cortices, SH-SY5Y cells, and mouse cor-
tical neurons was isolated with the TRIzol® Reagent using the
PureLink™ Micro-to-Midi Total RNA Purification System
(Invitrogen™ Life Technologies), following the manufac-
turer’s instructions. First-strand complementary DNAs
(cDNAs) were synthesized by reverse transcription of 1.5 of
total RNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems; Life Technologies)
according to the manufacturer’s instructions. Quantitative
PCR amplification was performed using a StepOne™ Real-
Time PCR System (Applied Biosystems) and TaqMan PCR
Master Mix with specific TaqMan Gene Expression Assays:
Hs00997789 for PS1, Hs00950933_m1 for nicastrin,
Hs00708570_s1 for PEN2, HS00211268_m1 for APH1A,
and Hs0029911_m1 for APH1B on SH-SY5Y cell RNA;
Mm00501184_m1 for PS1 on mouse cortical neuron RNA;
and Rn00569763_m1 for PS1 on rat brain hemi-cortex RNA.
GAPDH was amplified as a housekeeping marker
(Hs03929097 for SH-SY5Y cells, Mm99999915_g1 for
mouse cortical neurons, and Rn014626662_g1 for rat brain
hemi-cortices), and the transcript levels were calculated rela-
tive to GAPDH using the comparative 2−ΔCt method.
Behavioral Studies
The Y-maze alternation, active avoidance, and beam walking
tests were performed to analyze memory and learning func-
tions, as well as motor coordination. The tests were performed
2–4 h after the final administration of avagacestat.
Y-Maze Novel Spatial Recognition Memory This test is
based on the rodents’ natural curiosity to explore novel areas,
and the rats were tested as described elsewhere [25]. Briefly,
rats were placed into one of the arms of the Y-maze (start arm)
and allowed to explore the maze with one of the arms closed
for 3 min (training trial). After a 30-min inter-trial interval, the
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rats were returned to the Y-maze, placing them in the start arm,
and then the rats were allowed to freely explore all three arms
of the maze for 3 min (test trial). The number of entries into
and the time spent in each arm were registered manually by an
observer blinded to the rat’s treatment. The discrimination
ratio is a measure of the preference for the novel arm over
the familiar (old) arm, calculated as the Time spent in
Novel / Time spent in the (Novel + Old).
Active Avoidance The active avoidance task is designed to
test the ability of the rats to avoid an aversive event by first
learning to perform a specific behavior in response to a stim-
ulus. The test was performed on a single day and involved 50
trials per animal, as described previously [26].
Beam Walking Test The beam walking test assesses deficits
in fine motor coordination [27], although it is also a useful
assay to test for anxiety-like behavior [28] as it also causes
some anxiety in the animal. Motor coordination was tested on
a 1-m-long wooden stick (20 mm in diameter) situated ap-
proximately 1 m above the ground as described elsewhere
[29]. The number of slips (foot faults) and the latency to cross
(the time spent on the apparatus as an estimate of anxiety) are
scored.
Statistical Analysis
All data were analyzed using SigmaStat (version 3.5; Systat
Software, Inc.), determining exact p values by applying a
Student’s t test (two-tailed) or the Mann-Whitney rank-sum
test, when normality was rejected. The results are presented as
the means ± SEM.
Results
Inhibition of γ-Secretase by the GSI DAPT Increases
the PS1 in SH-SY5Yand Primary Neuronal Cultures
We addressed whether DAPT, a well-known GSI that targets
PS1 and reduces Aβ in vivo [30], alters PS1 expression and
protein levels in SH-SY5Y neuroblastoma cells. Exposure to
DAPT (5 μM) for 18 h did not affect cell viability (p = 0.6), as
evaluated by the MTS assay and in agreement with a previous
study [31]. We first corroborated the efficiency of an acute 18-
h treatment with DAPT (5 μM) to inhibit γ-secretase activity
by measuring the accumulation of the APP-CTF in cell ex-
tracts (Fig. 1a). PS1 undergoes endoproteolytic cleavage as
part of its maturation, generating N-terminal fragment (NTF)
and CTF [32], with very little full-length PS1 detectable in
wild-type cultured cells [33]. As expected, a predominant
band of ~ 29 kDa that corresponded to the PS1-NTF was
evident when immunoblots were probed with an anti-PS1-
NTF antibody, with little or no full-length PS1. The amount
of PS1-NTF was significantly higher in extracts from DAPT-
treated cells (32 ± 14%, p = 0.03) relative to the untreated
controls (Fig. 1a). Similarly, there was a significant increase
in the other γ-secretase components (nicastrin, PEN2, and
APH1) in DAPT-treated SH-SY5Y cells (Supplemental Fig.
1A). However, there was no parallel increase in the mRNA
encoding PS1 (Fig. 1a) or the other γ-secretase subunits
(Supplemental Fig. 1B), which remained similar in DAPT-
treated and untreated SH-SY5Y cells.
Likewise, repeatedDAPT treatment of mouse primary neu-
ronal cultures grown for 2 weeks and then treated daily with
DAPT (2 μM) over 4 days also augmented the amount of PS1
protein (64 ± 11%, p < 0.001; Fig. 1b), with unaltered mRNA
levels (Fig. 1b). Again, no cytotoxicity was observed during
the treatment (p = 0.4, as compared with cell viability in cells
treated with vehicle). Hence, the change in PS1 content
persisted when γ-secretase inhibition was maintained.
Effects of APP-CTF Over-expression on PS1 in SH-SY5Y
Neuroblastoma Cells
Since APP-CTF accumulation is a consequence ofγ-secretase
inhibition, we tested whether increasing APP-CTF mediated
the change in PS1 levels by transfecting SH-SY5Y cells with
APP-C99 cDNA, the β-secretase-derived CTF of APP. More
APP-CTF was evident in these cells following transfection
(48 h; Fig. 2a), with APP-C99 over-expression producing a
significant increase in the cellular PS1 content (65 ± 21%,
p = 0.007; Fig. 2b).
The GSI Avagacestat Alters the PS1 in Cultured Cells
and Its Content In Vivo
Avagacestat is one of the first GSI that undergone clinical
trials but discontinued development for AD because of a lack
of efficacy at phase 2 trial [34–36]. Avagacestat selectively
blocks the processing of APP substrates without notably af-
fecting Notch processing [37, 38]. We analyzed the effect of
avagacestat on PS1 in the primary neuronal cultures, where
exposure to this GSI (2 μM) on four consecutive days in-
creased the amount of PS1 relative to the controls exposed
to the vehicle alone (41 ± 9%, p = 0.007; Fig. 3). There was
no cell death in cultures treated with avagacestat, as evaluated
by the MTS assay (p = 0.5).
Avagacestat was also administered orally to rats in a 40mg/
kg dose. In previous experiments in rats to which doses of 2–
100 mg/kg avagacestat were used, a 40 mg/kg dose demon-
strated significantly reduced Aβ in the brain, with no abnor-
malities detected [37, 39]. Acute treatment served to probe
that avagacestat inhibits the processing of APP-CTF in treated
rats, promoting their accumulation in animals treated with a
single dose (Fig. 4a). We also tested whether avagacestat
5050 Mol Neurobiol (2018) 55:5047–5058
treatment increases PS1 in the brain of rats as part of a rebound
effect, and we extended our analysis to include behavioral
tests. When avagacestat (40 mg/kg) was administered orally
to rats once daily for 4 days, there was apparently no effect on
the amount of APP-CTF in the brain after treatment and PS1
levels remained unaltered (Supplemental Fig. 2). Conversely,
treatment for 21 days significantly diminished the APP-CTF
in the brain (79 ± 5%, p = 0.005; Fig. 4b). This unexpected
decrease in APP-CTF, after prolonged GSI treatment,
prompted the analysis of the levels of other γ-secretase sub-
strates. ApoER2, a liporeceptor for ApoE/Reelin, is also a γ-
secretase substrate [31], and a significant decrease in
ApoER2-CTF (72 ± 9%, p = 0.03; Fig. 4b) was also detected
in rats exposed to avagacestat, relative to the control rats. The
increase in the rate of processing of γ-secretase substrates,
APP-CTF and ApoER2-CTF, paralleled with an increase in
PS1-NTF (29 ± 9%, p = 0.008: Fig. 4c). Again, the
avagacestat-induced increase in PS1 protein was not
paralleled by an increase in its mRNA transcripts (Fig. 4c).
We recently demonstrated the presence of heteromeric PS1
complexes in human and rodent CSF (CSF-PS1), the
proportion of such stable, large molecular mass complexes
being associated to AD status [40, 41]. In Western blots
probed with an antibody against the PS1-NTF, predominant
bands of approximately 100, 80, and 70 kDa were detected,
corresponding to CSF-PS1 SDS-stable complexes previously
characterized [40], as well a 29-kDa band corresponding to
monomeric PS1-NTF. Unexpectedly, the immunoreactivity
for the 100-kDa complexes diminished in 21-day
avagacestat-treated rats relative to the control rats
(57 ± 10%, p = 0.03; Fig. 5), whereas no notable changes were
observed in rats treated for 4 days with avagacestat (Fig. 5).
Finally, we assessed potential behavioral, memory, and
learning changes in rats treated for 21 days with avagacestat
using the novel spatial recognition memory, the active avoid-
ance, and the beamwalking tests. Avagacestat-treated animals
displayed no differences in the novel spatial recognition mem-
ory in the Y-maze, with similar discrimination between arms,
nor delayed alternation, when compared to the control rats
(Fig. 6a). We also observed similar abilities of avagacestat
and vehicle-treated rats to learn the active avoidance task
and avoid the aversive event (Fig. 6b). However, while
Fig. 1 GSI DAPT treatment augments PS1 in SH-SY5Y cells and in
mouse primary neurons. a SH-SY5Y cells were treated for 18 h
(acutely) with DAPT (5 μM) or the vehicle alone (control; Ctrl). Cell
extracts were probed with antibody C1-6.1, against the APP C-terminal,
to demonstrate the accumulation of the APP-CTF in treated cells as a
result of the inhibition of γ-secretase processing. Cell extracts were also
probed for PS1 with an anti-N-terminal antibody. Equivalent amounts of
protein were loaded in each lane, and GAPDH was used as a loading
control. Representative blots and densitometric quantification of the
immunoreactivity are shown. Relative expression of PS1 mRNA was
also analyzed by qRT-PCR. Transcript levels were calculated by the
comparative 2−ΔCt method with respect to GAPDH cDNA. b Primary
neurons were treated with DAPT (2 μM) or the vehicle alone (Ctrl) for
four consecutive days. Cell extracts were probed for APP-CTF and PS1
and for GAPDH as a loading control. The densitometric quantification for
PS1-NTF is shown, as well the relative mRNA levels of the PS1
transcript. The data represent the means ± SEM of at least n = 10
independent determinations (obtained from two independent sets of
experiments): *p < 0.05
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avagacestat-treated rats did not display any alterations in the
ability to cross a round beam, revealing no gross motor
deficits, significant differences were detected in the latency
time to cross the beam, probably indicating higher levels of
anxiety (Fig. 6c).
Discussion
The possibility that levels and activities of secretases are
affected in the brain of AD subjects has been studied inten-
sively [5, 8]. However, whether their inhibition by GSIs can
induce persistent compensatory changes in the brain has yet
to be addressed. It is known that neurotransmitter trans-
porters potentially undergo alterations to gene transcription,
mRNA translation/stability, post-translational, protein traf-
ficking, cytoskeletal interactions, and oligomerization in re-
sponse to chronic drug administration [42]. Indeed, an up-
regulation of proteins targeted by pharmacological inhibition
has also been documented [18–20]. Here, we demonstrate
that GSIs can induce a feedback mechanism that results in
accumulation of PS1 in different cell models. A similar ele-
vation of brain PS1 was identified in 21-day avagacestat-
treated rats, which also displayed an increasing rate of pro-
cessing of the γ-secretase substrates APP-CTF and
ApoER2-CTF, indicative of a rebound effect. These effects
could be related to the reported failure of GSIs to achieve
long-term Aβ regulation and their contribution to rather than
the palliation of the AD pathology.
We found an increase in PS1 after a single day of DAPT
administration to SH-SY5Y cells. Similar results were obtain-
ed in primary neuronal cultures treated for 4 days with DAPT
and in rats treated for 21 days with avagacestat. The increase
in PS1 protein was not paralleled by changes in PS1 mRNA
content, indicating that this increase is not mediated by tran-
scriptional upregulation. At present, the mechanism by which
PS1 levels are enhanced by GSI administration remains un-
known. Interestingly, over-expression of the β-secretase-
derived APP fragment C99 could also mediate an increase in
PS1. There is evidence that the accumulation of APP-C99
may be directly implicated in neurodegeneration and cogni-
tive alterations [43]. Previous evidences indicate that excess in
other γ-secretase substrates can compromise γ-secretase cat-
alytic activity, being accompanied by an increase in PS1 levels
[21]. Remarkably, it has been demonstrated that accumulation
of APP-C99 can cause an impaired lysosomal-autophagic
function [44]. Hence, it seems desirable to investigate whether
an excess of γ-secretase substrates may result in transient
stabilization of PS1/γ-secretase substrate complexes, interfer-
ing in the effective clearance of PS1. Similarly, the stabiliza-
tion of PS1/GSI complexes during sustained γ-secretase inhi-
bition could interfere in the clearance/turnover of PS1. Indeed,
decreased intracellular clearance of PS1 may also reflect the
reduction of the CSF-PS1 complex levels, although how PS1
reaches the CSF is unknown.
Fig. 2 Effects of the modulation of APP-CTF expression on PS1 levels.
SH-SY5Y cells were transfected with APP-C99 cDNA, the β-secretase-
derived CTF of APP, or with a control vector (Ctrl). a Immunodetection
of APP-CTF with the anti-APP C-terminal antibody C1-6.1 served to
assess the efficiency of over-expression. The identity of the increased
immunoreactive band was also tested with the 6E10 antibody, which
recognizes an epitope present in the N-terminal of APP-C99 (not
shown). b The immunodetection and densitometric quantification of
PS1 immunoreactivity in transfected cells are shown. The data are
presented relative to control cells, expressed as the means ± SEM of at
least 12 independent determinations (obtained from two independent sets
of experiments): *p = 0.007
Fig. 3 Increased PS1 levels in neurons treated with the GSI, avagacestat.
Primary neurons were treated with avagacestat (2 μM, Avgct) or the
vehicle alone (Ctrl), and the cell extracts were probed for a APP-CTF
and b PS1. Representative blots and their densitometric quantification are
shown. The data presented are relative to the Ctrl cells, expressed as the
means ± SEM of at least ten independent determinations (obtained from
two independent sets of experiments): *p = 0.007
5052 Mol Neurobiol (2018) 55:5047–5058
In this context, it has been demonstrated that changes in
PS1 ubiquitination can alter cellular levels of PS1 and other γ-
secretase subunits, leading to an alteration in the metabolism
of APP [45, 46]. Therefore, a chronic treatment with GSIs
may cause a sustained accumulation of PS1 leading a rebound
effect with gain in γ-secretase activity. In this regard, although
avagacestat has demonstrated effect in the accumulation of
APP-CTF (acute treatment in rats), prolonged exposition to
Fig. 4 Effect of prolonged inhibition of γ-secretase by avagacestat on γ-
secretase substrates and PS1 in the cortex of rats treated for 21 days. Rats
were treated daily with the GSI avagacestat (40 mg/kg, Avgct) or the
vehicle alone (control; Ctrl) for 21 days, and they were sacrificed 4 h
after the last dose. a As a control of the effective γ-secretase inhibition
by the GSI in the brain, APP-CTF levels (probed with antibody C1-6.1)
were firstly evaluated in rats sacrificed 4 h after a single dose of
avagacestat (n = 6 per group). b The levels of APP-CTF and ApoER2-
CTF were estimated in rats treated with avagacestat for 21 days;
representative blots and densitometric quantifications are shown. c PS1
levels were also evaluated inWestern blots of the same brain hemi-cortex
extracts. GAPDH was used as a loading control. d Relative PS1 mRNA
was analyzed by qRT-PCR in the other rat hemi-cortices obtained after
21 days of treatment (n = 10 per group). The data are presented relative to
the control rats and expressed as the means ± SEM (n = 10 per group): *
p < 0.05 significantly different from the controls
Fig. 5 Effect of avagacestat on PS1 levels in CSF of rats treated for 4 and
21 days. Rats were administered avagacestat (40 mg/kg, Avgct) or the
vehicle alone (Ctrl) daily over 4 or 21 days. Soluble PS1 complexes were
also evaluated in Western blots of CSF samples from Avgct-treated and
control rats (n = 7 per group). CSF-PS1 complexes were detected with
and N-terminal antibody, which predominantly recognized stable
complexes of approximately 100 kDa, together with less abundant 80-,
70-, and 50-kDa complexes, as well monomers of 29 kDa. Previous
studies indicated that these CSF-PS1 complexes represent aggregates of
PS1-NTF and CTF [40, 41]. The densitometric quantification of the
major CSF-PS1 100-kDa complex is shown. The data are presented
relative to the control rats, expressed as the means ± SEM: *p < 0.05
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the GSI (21 days of treatment in rats) has lead to PS1 accu-
mulation. An increase in PS1 levels, even maintained in GSI
treatment, could result in an increasing rate of substrate pro-
cessing during the oscillations in the effective inhibitory con-
centration of the drug, derived of the half-life and QD dosing.
Moreover, other alternatives are suitable. There are subtle
differences in the subcellular accumulation of APP-CTF in
PS1-deficient cells, with no obvious redistribution of the
full-length protein [47]. Distinct subcellular locations of PSs
have been shown to contribute to substrate specificity [48],
and changes in the subcellular distribution of BACE1 induced
by Aβ oligomers have been related to the pathogenesis of AD
[49]. In brief, both post-translational and turnover/degradation
mechanisms may participate in the pernicious response to GSI
and deserve investigation. Moreover, we cannot discard that
other enzymes distinct from PS1, or acting in parallel, could
be involved in the rebound effect, with an increased rating of
γ-secretase substrate processing during prolonged inhibition.
Chronic inhibition of PS1 with GSI has led to toxic side
effects in clinical trials [37, 50, 51]. These adverse effects
were thought to be related with the regulation of Notch activ-
ity by γ-secretase, a protein that is important for cell-to-cell
communication and that has also been implicated in cancer
[52]. Toxic side effects have been noted in clinical trials con-
ducted with Notch-sparing GSIs as well as non-selective
GSIs, although the true selectivity of the former is not clear
[8]. Indeed, dozens of additional substrates for γ-secretase
have been identified and, thus, non-selective GSIs would
probably interfere with multiple cellular events [53, 54].
Currently, clinical trials with semagacestat (LY450139), an
earlier-generation GSI that does not discriminate well between
APP and Notch, have been discontinued, similar to clinical
trials with avagacestat. Furthermore, the development of an-
other Notch-sparing GSI, begacestat (GSI-953) [55], has also
been discontinued for reasons that are not clear (discussed in
De Strooper and Chávez-Gutiérrez [56]).
The therapeutic effect of GSIs appears to be transient, and
the possibility of decelerating or halting cognitive deteriora-
tion also falls below expectations. At 2 years, no significant
differences were observed in key clinical outcomemeasures in
an avagacestat phase 2 trial, yet progression to dementia was
more frequent in the prodromal AD cohort vs the observation-
al cohort [36]. Similarly, semagacestat made AD patients cog-
nitively worse in a phase 3 trial [57]. In Tg2576 mice, a 1-day
treatment with two GSIs significantly ameliorated cognitive
deficits (acute effects) but these effects disappeared when an
8-day treatment schedule was employed. Indeed, prolonged
treatment with GSIs impairs spatial workingmemory and cog-
nitive function [58]. In our study, an augmented latency time
in the beam walking test in wild-type rats treated for 21 days
with avagacestat suggests that some behavioral issues are af-
fected by GSIs. This phenomenon is consistent with the
dampening of initiative and the anxiety that are common neu-
ropsychiatric features of AD [59, 60]. Interestingly, the con-
ditional double presenilin knockout mice has observably al-
tered anxiety-like behavior [61], and less anxiety is also
displayed by transgenic mice expressing mutants PS1-
A246E [62] and PS2-N141I [63]. An association of PS1 with
altered anxiety-like behavior has been suggested [64] and is
worthy of further investigation. The subtle alterations in be-
havioral tests in wild-type rats are inconclusive since we did
not use an animal model with an impaired condition, and nor
did we demonstrate a direct association between altered
anxiety-like behavior and increased brain PS1 levels.
However, we speculate that part of the impairment ob-
served in clinical trials involving GSI use on humans
and in chronically treated animals could be due to re-
bound increases in PS1.
Although simple in concept, the validation of amyloid drug
targets, and specifically that of GSIs, has proved complex in
practice. Earlier studies indicated that the acute oral adminis-
tration of DAPT to APPV717F transgenic mice reduces the Aβ
in the brain [30]. The use of canine [65] and non-human pri-
mate [66] models also served to demonstrate that GSIs de-
crease the Aβ peptides in the CSF. However, it is well
established that the levels of AD CSF diminish when there
is an increase in brain deposition of Aβ. Thus, changes in
CSF-Aβ are unlikely to provide significant information about
Fig. 6 Results of the behavioral tests in rats treated 21 days with
avagacestat. a Novel spatial recognition memory in the Y-maze in rats
treated with avagacestat for 21 days (Avgct) and in the vehicle-treated
controls (Ctrl). The time spent in each arm was recorded in order to
calculate the discrimination index after a 30-min inter-trial interval. b
Result of the active avoidance test documenting the number of attempts
made to avoid the foot shock. cBeamwalking test in which the number of
slips and the latency to cross were scored. The values are the
means ± SEM (n = 10 for each group): *p < 0.05
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therapies aimed at reducing Aβ production, and a lowering of
CSF-Aβ levels is unlikely to be a suitable measure of target
engagement [67].
In this regard, acute administration of avagacestat robustly
reduces CSFAβ40 and Aβ42 levels similarly in rats and dogs
[39]. Moreover, the administration of a single dose of
avagacestat to healthy humans, as well over a 28-day sched-
ule, also markedly decreases Aβ40 and Aβ42 concentrations
in the CSF [68, 69]. However, exploratory CSF amyloid iso-
forms displayed a dose-dependent but not significant reduc-
tion in a small subset of patients in a phase 2 trial, and while
well tolerated, lower doses did not affect the Aβ40 and Aβ42
levels in treated patients [35]. Similarly, earlier studies with
semagacestat in volunteers indicated unchanged levels of
CSF-Aβ [70], although in another study, single oral doses of
semagacestat appeared to decrease Aβ levels in the CSF of
healthy volunteers [71]. No significant reduction in CSF
Aβ42 or Aβ40 level was detected in a phase 2 safety trial
[72], a finding verified by mass spectrometry analysis of the
same samples [73]. Instead, an increase in shorter Aβ peptides
(Aβ1–14, Aβ1–15, and Aβ1–16) was identified, probably
due to increased substrate availability (APP-C99) for α-
secretase [73]. Interestingly, semagacestat produced a de-
crease in plasma Aβ concentrations in a 6-h interval following
drug administration, returning to baseline and then transiently
increasing the Aβ concentrations [13]. It was suggested that
semagacestat might lower Aβ at high concentrations but
cause Aβ elevation at low concentrations [15]. A structurally
related γ-secretase inhibitor, LY-411575, also elevated plasma
Aβ40 and Aβ42 in Tg2576 mice [14]. A biphasic activation-
inhibition dose-response curve for GSIs was proposed to ex-
plain these changes in Aβ secretion [74]. However, these
changes may also be indicative of a transient overshooting
or rebound effect, since an increase in plasma Aβ40 and
Aβ42 has been described in Tg2576 mice chronically treated
with DAPT [12].
Here, we addressed the efficiency of GSIs to inhibit PS1 by
assessing changes in the cellular γ-secretase substrate APP-
CTF. As expected, the accumulation of APP-CTF served to
assess the inhibitory effect of DAPTon PS1 in cellular models
and also that of avagacestat. Accordingly, we were able to
detect accumulation in the brain levels of APP-CTF in acutely
treated rats (sacrificed 4 h after a single dose). However,
sustained inhibition of γ-secretase activity over 21 days re-
vealed decreased APP-CTF levels, suggesting that the consol-
idation of higher PS1 levels in reaction to chronic inhibition
results in an increase in γ-secretase activity, at least in the
intervals between GSI administration. The consolidation of
higher levels of PS1 might indiscriminately affect all γ-
secretase substrates, such as ApoER2 and others, further ex-
acerbating the AD pathology. Interestingly, administration of
GSIs increased APP-CTF in H4 cells over-expressing APP,
although this increase was unexpectedly attenuated at high
concentrations [58]. Elsewhere, APP-C99 levels increase in
CHO cells co-expressing APP and PS1 relative to cells ex-
pressing APP alone, and PS1 can stabilize APP-CTF indepen-
dent of γ-secretase activity [75]. Hence, the relationship be-
tween the substrate and the catalytic enzyme appears to be
more complex than might at first appear.
PS1 also participates in other cell functions [76, 77], and
therefore, the increase in PS1 after GSI administration may
influence distinct cellular effects, even if this subunit is not-
catalytically active. In this regard, PS1 has been implicated in
the physiological maturation and glycosylation of several key
proteins implicated in AD, such as nicastrin [78], BACE1
[79], acetylcholinesterase [80], and others, including APP
[81]. Hence, the over-expression of either the wild-type or
mutant PS1 disturbs glycoprotein processing [82]. Further re-
search will be needed to clarify the influence of increased PS1,
under prolonged GSI administration, in the role of PS1 in their
non-proteolytic functions, and possible interference with the
therapeutic response.
Conclusions
We show here that administration of GSIs result in a rebound
increase in PS1 levels in cellular and animal models, which
must be taken into consideration when using such compounds
in AD therapy. Indeed, our results indicate that the effect of
GSI inhibitors on APP processing failed to have a long-term
effect in treated rats, possibly due to the persistent PS1 eleva-
tion in reaction to chronic inhibition.
The outcomes of the clinical trials with GSIs have been
disappointing, although this may not represent the end of the
development of these drugs to treat AD. The data presented
here indicate that the therapeutic benefits of GSIs and related
drugs should continue to be explored, or at least, we can ex-
tract information that will help understand the failure of GSIs
in AD trials [83]. Hence, synthesizing new GSIs that distin-
guish strongly between APP and Notchmay serve to lower the
required dose, yet it still might not solve the unexplained and
unexpected problem of the facilitation of toxic side effects and
the AD-derived pathogenesis. The failure of GSIs in clinical
trials highlights the need for a systematic re-examination of γ-
secretase biology, including further characterization of the
mechanisms related to the response to chronic inhibition.
Elucidating the mechanisms involved, the complex self-
regulation of γ-secretase is also important to optimize thera-
pies based on γ-secretase modulation. A potent inhibition/
modulation of secretase activities will result in the unbalanced
generation of proteolytic fragments of APP (and fragments
from other substrates), which could determine a self-
regulatory response that will require further analysis for new
secretase inhibitors/modulators designed to specifically inhib-
it the Alzheimer process.
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In this regard, γ-secretase modulators (GSMs), which
only block the γ-secretase cleavage of APP to generate
the Aβ42, with no changes in the production of total
Aβ, were also noticed to have negative outcomes [84].
The clinical development of BACE1 inhibitors is also
being intensely pursued, and several promising BACE1
inhibitors have entered human clinical trials [85], but a
sign of toxicity forced to stop the earliest trials
(discussed in Lahiri et al. [86]). For a successful devel-
opment of new secretase inhibitors/modulators, it is
needed to better understand the cellular response to
the sustained inhibition/modulation of the secretase
activity.
Despite its enzymatic capacity, γ-secretase activity ap-
pears tightly regulated by many cellular components, in-
cluding its own subunits, modulatory partners, and sub-
strates, as well as by an array of cellular events [87].
Furthermore, GSIs are presently explored in clinical trials
as potential therapeutic agents in cancer, targeting Notch,
although a number of mechanism-based adverse events
again emerge [88]. As the therapeutic benefits of GSIs
and related drugs continue to be explored, a better under-
standing of the response of PS1 to chronic inhibition will
become more necessary.
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